BioVie to highlight neuro and liver disease programs in June 2 investor webinar

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will host an investor webinar on June 2 at 4:15 p.m. ET featuring CEO Cuong Do.

The discussion will focus on bezisterim (NE3107), BioVie’s investigational oral drug candidate targeting neuroinflammation and insulin sensitivity for conditions including Parkinson’s disease, Long COVID and Alzheimer’s disease.

Management will also provide updates on BIV201 for refractory ascites linked to liver cirrhosis. A live Q&A session will follow the presentation.